Viable Cells

MDA231-DOX[r] - CELLS

$995.00

MDA231-DOX[r] viable cells.

MDA231-DOX[r] cells are 2.7-fold more resistant to inhibition by DOXORUBICIN than parental MDA-MB-231 cells. DOXORUBICIN IC50s for MDA231-DOX[r] and parental MDA-MB-231 cells are 7.4 nM and 2.8 nM, respectively (MTT assay). MDA231-DOX[r] cells were established following 6 months of continuous in vitro exposure of parental MDA-MB-231 cells to DOXORUBICIN.

Price: $995.00

K562-DAS[r] - CELLS

$495.00

K562-DAS[r] viable cells.

KK562-DAS[r] cells are 109-fold more resistant to inhibition by DASATINIB than parental K562 cells. DASATINIB IC50s for K562-DAS[r] and parental K562 cells are 4.9 nM and 0.05 nM, respectively (MTT assay). K562-DAS[r] cells were established following 8 months of continuous in vitro exposure of parental K562 cells to DASATINIB.

Price: $495.00

K562-IMA[r]+DAS[r] - CELLS

$995.00

K562-IMA[r]+DAS[r] Viable Cells.

K562-IMA[r]+DAS[r] cells are resistant to both IMATINIB and DASATINIB. Compared with parental K562 cells, K562-IMA[r]+DAS[r] cells are 129-fold more resistant to IMATINIB and 94-fold more resistant to IMATINIB: The in vitro IC50s for K562-IMA[r]+DAS[r] and parental K562 cells are 13.0 µm and 0.10 µm (IMATINIB), and 4.5 nM and 0.05 nM (DASATINIB), respectively.

Price: $995.00

K562-IMA[r] - CELLS

$995.00

K562-IMA[r] viable cells.

K562-IMA[r] cells are 145-fold more resistant to inhibition by IMATINIB than parental K562 cells: IMATINIB IC50s for K562-IMA[r] and parental K562 cells are 14.7 µM vs 101 nM, respectively (MTT assay). K562-IMA[r] cells were established following 8 months of continuous in vitro exposure of parental K562 cells to IMATINIB.

K562-IMA[r] cells are available through a licensing agreement with ChemoScreen. The listed price is for a two-year license.

Price: $995.00

K562-NIL[r] - CELLS

$995.00

K562-NIL[r] Viable Cells.

K562-NIL[r] cells are 15-fold more resistant to inhibition by NILOTINIB than parental K562 cells: NILOTINIB IC50s for K562-NIL[r] and parental K562 cells are 87 nM vs 5.9 nM, respectively. K562-NIL[r] cells were established following 8 months of continuous in vitro exposure of parental K562 cells to NILOTINIB.

K562-NIL[r] cells are available through a licensing agreement with ChemoScreen. The listed price is for a two-year license.

Price: $995.00

K562-IMA[r]+PON[r] - CELLS

$995.00

K562-IMA[r]+PON[r] Viable Cells.

K562-IMA[r]+PON[r] cells are resistant to both IMATINIB and PONATINIB. Compared with parental K562 cells, K562-IMA[r]+PON[r] cells are 119-fold more resistant to IMATINIB and 4,255-fold more resistant to PONATINIB: The in vitro IC50s for K562-IMA[r]+PON[r] and parental K562 cells are 12.0 µm and 0.10 µm (IMATINIB), and 80 nM and 0.02 nM (PONATINIB), respectively.

Price: $995.00

K562-PON[r] - CELLS

$995.00

K562-PON[r] Viable Cells.

K562-PON[r] cells are 200-fold more resistant to PONATINIB than parental K562 cells: In vitro IC50s are 3.8 nM vs 0.02 nM, respectively. K562-PON[r] cells were established following 8 months of continuous in vitro exposure of parental K562 cells to PONATINIB.

K562-PON[r] cells are available through a licensing agreement with ChemoScreen. The listed price is for a two-year license.

Price: $995.00
Subscribe to RSS - Viable Cells